Retraction of Semaglutide-NAION Link: Original Study Withdrawn Due to Flawed Data

Semaglutide, a widely prescribed glucagon-like peptide-1 receptor (GLP-1R) agonist, is highly effective for managing type 2 diabetes and obesity due to its glucose-dependent insulinotropic effects and appetite suppression. However, like all medications, it carries potential side effects. Recently, a concerning signal emerged regarding a possible association between semaglutide use and non-arteritic anterior ischemic optic neuropathy (NAION), a severe ophthalmic condition characterized by sudden, painless vision loss due to impaired blood flow to the optic nerve head. This potential link, initially reported in some observational studies and case reports, created significant uncertainty for both clinicians prescribing semaglutide and patients using it, prompting a need for rigorous re-evaluation of such safety claims.